Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:09 AM
Ignite Modification Date:
2025-12-25 @ 2:09 AM
NCT ID:
NCT03719560
Eligibility Criteria:
Inclusion Criteria:
* New diagnosis of diffuse large B-cell lymphoma, planned first-line therapy using the standard rituximab- and anthracycline-containing regimens
* No central nervous system involvement on initial staging
* Performance status of 0 or 1 (Eastern Cooperative Oncology Group scale)
* Renal function: creatinine clearance \>45 ml/min
* Not pregnant; agreeable to contraception
* Written informed consent
* High risk for central nervous system recurrence as determined by one of the following high-risk features:
1. high central nervous system International Prognostic Index,
2. testicular, breast, or uterine involvement,
3. dual expresser or double/triple-hit status,
4. HIV positive status, or
5. Molecularly defined high-risk subtype.
Exclusion Criteria:
* pregancy
* unable to provide informed consent
* significant comorbidity in the investigator's judgement
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03719560
Study Brief:
Protocol Section:
NCT03719560